Vertex Pharmaceuticals (VRTX – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Terence ...

Despite healthcare sector struggles, Vertex Pharmaceuticals has outperformed ... diabetes, and kidney disease follows this proven playbook of tackling complex diseases with high unmet needs.

Jan 28 (Reuters) - The U.S. FDA has approved Novo Nordisk's (NOVOb.CO), opens new tab Ozempic for reducing the risk of kidney failure and disease progression, as well as death due to heart ...

Vertex has built an empire in cystic fibrosis ... The company's methodical expansion into pain, diabetes, and kidney disease follows this proven playbook of tackling complex diseases with high ...

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq ... including acute and neuropathic pain, APOL1-mediated kidney disease, IgA nephropathy, primary membranous nephropathy, autosomal ...

Needham analyst Joseph Stringer has maintained their neutral stance on VRTX stock, giving a Hold rating today.Invest with Confidence: Follow ...

Vertex has built an empire in cystic fibrosis (CF) treatment, recently crowning its dominance with Alyftrek's approval last month. This latest CF drug adds even more firepower to a franchise ...

A Phase 3 clinical trial found that injections of the semaglutide medication once weekly reduced the risk of kidney disease worsening by 24% in people who also had diabetes. It also reduced the ...

With the biotech company's stock already posting impressive gains of over 9% in early 2025, it's worth examining whether Vertex stock remains a compelling buy right now. Image source: Getty Images.